Author

Y. Sakai-Tagawa

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Assay:metagenomics· 1

Frequent Co-Authors

Y. Kawaoka· 3 shared K. Iwatsuki-Horimoto· 2 shared M. Imai· 2 shared M. Kiso· 2 shared N. Ohmagari· 2 shared A. Takenaka-Uema· 1 shared B. Korber· 1 shared D. Larson· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Y. Kawaoka

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivPreprintAug 26, 2022

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

R. Uraki, S. Iida, P. J. Halfmann…·Y. Kawaoka

This study evaluates the replicative ability and pathogenicity of SARS-CoV-2 BA.2.75 isolates in Syrian hamsters, finding higher lung replication and focal pneumonia compared to BA.2 and BA.5.

DOI 10.1101/2022.08.26.505450

mouseexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintMay 16, 2022

Isolation of bat sarbecoviruses of SARS-CoV-2 clade, Japan

S. Murakami, T. Kitamura, H. Matsugo…·T. Horimoto

The paper isolates and characterizes SARS-CoV-2 clade sarbecoviruses from Japanese bats, showing host-specific replication and genetic variation in the S1 region.

DOI 10.1101/2022.05.16.492045

mousemetagenomics

𝕏 PostBluesky

MicrobiologybioRxivPreprintApr 22, 2020

The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects

M. Yamamoto, M. Kiso, Y. Sakai-Tagawa…·J.-i. Inoue

This study shows nafamostat inhibits SARS-CoV-2 infection in vitro by blocking TMPRSS2-mediated fusion, with potency exceeding its blood concentration, suggesting it as a potential COVID-19 treatment.

DOI 10.1101/2020.04.22.054981

humanbulk RNA-seq

𝕏 PostBluesky